AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7947503 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG treatment (10,000 i.u. initially, then 5000 i.u. twice weekly until miscarriage or the tenth week of pregnancy)
Number of subjects: 191
Study 7947503 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG treatment in women with follicular phase luteinising hormone > 10 iu/l
Number of subjects: 191
Study 7947503 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG treatment with clomiphene for ovulation induction
Number of subjects: 191
Study 7947503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 7947503 — intervention group
Group type: COMPARATOR
Intervention: Placebo in women with follicular phase luteinising hormone > 10 iu/l
Number of subjects: 191
Study 7947503 — intervention group
Group type: COMPARATOR
Intervention: Placebo with clomiphene for ovulation induction
Number of subjects: 191
Study 2644594 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics after hospital discharge
Number of subjects: 163
Study 2644594 — intervention group
Group type: COMPARATOR
Intervention: No oral antibiotics after hospital discharge
Number of subjects: 163
Study 29143569 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenching/grinding
Number of subjects: 4204
Study 29143569 — intervention group
Group type: EXPERIMENTAL
Intervention: Clicking
Number of subjects: 4204
Study 29143569 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty chewing
Number of subjects: 4204
Study 29143569 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty closing
Number of subjects: 4204
Study 29143569 — intervention group
Group type: COMPARATOR
Intervention: Missing teeth association with clenching/grinding
Number of subjects: 4204
Study 29143569 — intervention group
Group type: COMPARATOR
Intervention: Missing teeth association with difficulty chewing
Number of subjects: 4204
Study 29143569 — intervention group
Group type: COMPARATOR
Intervention: Age and gender effects
Number of subjects: 4204
Study 28329386 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap group (1-hour nap opportunity at 14:00 following each sleep restriction night)
Number of subjects: 57
Study 28329386 — intervention group
Group type: COMPARATOR
Intervention: No nap group
Number of subjects: 57
Study 28329386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study 26271018 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Based Early Intervention
Number of subjects: 59
Study 26271018 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 59
Study 23291509 — intervention group
Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy followed by bimanual training (mCIMT-BiT)
Number of subjects: 52
Study 23291509 — intervention group
Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy (mCIMT)
Number of subjects: 52
Study 23291509 — intervention group
Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 52
Study 23291509 — intervention group
Group type: EXPERIMENTAL
Intervention: mCIMT-BiT
Number of subjects: 52
Study 21474111 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborative rehearsal as a secondary task
Number of subjects: 0
Study 21474111 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rehearsal
Number of subjects: 0
Study 21474111 — intervention group
Group type: COMPARATOR
Intervention: Control condition with no secondary task
Number of subjects: 0
Study 17530428 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate exercise group (IEG) - 12 weeks of supervised aerobic and resistance exercise, three times per week
Number of subjects: 58
Study 17530428 — intervention group
Group type: COMPARATOR
Intervention: Delayed exercise group (DEG) - completed the program during the next 12 weeks
Number of subjects: 58
Study 16689010 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpi Yiqi Huoxue Decoction (JYHD)
Number of subjects: 58
Study 16689010 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-infective and symptomatic therapy only)
Number of subjects: 58
Study 12658059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg)
Number of subjects: 51
Study 12658059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30 mg)
Number of subjects: 51
Study 12658059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lisinopril and nifedipine GITS
Number of subjects: 51
Study 12658059 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 51
Study 10636971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 40
Study 10636971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9024279 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) bolus and NS infusion
Number of subjects: 11
Study 9024279 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (NAL) bolus (4 mg) and NAL infusion (2 mg/h)
Number of subjects: 11
Study 9024279 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (NS) bolus and oCRH infusion (1 microgram/kg.h; maximum, 75 micrograms/h)
Number of subjects: 11
Study 9024279 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (NAL) bolus and both NAL and oCRH infusions
Number of subjects: 11
Study 8475703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen tonometry
Number of subjects: 132
Study 8475703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen tonometry by GPs
Number of subjects: 132
Study 3639538 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐paced response condition
Number of subjects: 105
Study 3639538 — intervention group
Group type: COMPARATOR
Intervention: fast‐paced response condition
Number of subjects: 105
Study 3639538 — intervention group
Group type: COMPARATOR
Intervention: slow‐paced response condition
Number of subjects: 105
Study 30744053 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy learning. Together. (intervention group)
Number of subjects: 1144
Study 29037627 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 3 MHz, 1.5 w/cm2 Ultrasound
Number of subjects: 50
Study 29037627 — intervention group
Group type: COMPARATOR
Intervention: Sham Ultrasound
Number of subjects: 50
Study 25977276 — intervention group
Group type: EXPERIMENTAL
Intervention: VASOGRADE-Green (modified Fisher scale 1 or 2 and WFNS 1 or 2)
Number of subjects: 746
Study 25977276 — intervention group
Group type: EXPERIMENTAL
Intervention: VASOGRADE-Yellow (modified Fisher 3 or 4 and WFNS 1-3)
Number of subjects: 746
Study 25977276 — intervention group
Group type: EXPERIMENTAL
Intervention: VASOGRADE-Red (WFNS 4 or 5, irrespective of modified Fisher grade)
Number of subjects: 746
Study 25977276 — intervention group
Group type: EXPERIMENTAL
Intervention: VASOGRADE overall
Number of subjects: 746
Study 24450889 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy for 9 months
Number of subjects: 78744
Study 24450889 — intervention group
Group type: COMPARATOR
Intervention: Control (no isoniazid preventive therapy)
Number of subjects: 78744
Study 24450889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clusters (mass screening and treatment)
Number of subjects: 78744
Study 24450889 — intervention group
Group type: COMPARATOR
Intervention: Control clusters (no intervention)
Number of subjects: 78744
Study 22672970 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg/m² weekly gemcitabine with 3D conformal radiotherapy delivering 55 Gy in 20 fractions over 4 weeks (Arm B)
Number of subjects: 111
Study 22672970 — intervention group
Group type: COMPARATOR
Intervention: 3D conformal radiotherapy delivering 55 Gy in 20 fractions over 4 weeks without gemcitabine (Arm A)
Number of subjects: 111
Study 19128941 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) trials
Number of subjects: 105
Study 19128941 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch trials
Number of subjects: 105
Study 19128941 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials funded by the pharmaceutical industry
Number of subjects: 105
Study 19128941 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically significant results
Number of subjects: 105
Study 17496226 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy based on Fe(NO) measurements (n = 58)
Number of subjects: 118
Study 17496226 — intervention group
Group type: COMPARATOR
Intervention: British Thoracic Society guidelines (control group, n = 60)
Number of subjects: 118
Study 17496226 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy based on Fe(NO) measurements
Number of subjects: 118
Study 12932065 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.0625% with sufentanil 10 microg
Number of subjects: 129
Study 12932065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% with sufentanil 10 microg
Number of subjects: 129
Study 12932065 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.0625% with sufentanil 10 microg
Number of subjects: 129
Study 12932065 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 129
Study 10926311 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg ALA orally per day over 6 weeks
Number of subjects: 18
Study 10926311 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ALA intravenously over 15 minutes
Number of subjects: 18
Study 10926311 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously over 15 minutes
Number of subjects: 18
Study 9006239 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Network (SN)
Number of subjects: 1265
Study 9006239 — intervention group
Group type: EXPERIMENTAL
Intervention: Information Media (IM)
Number of subjects: 1265
Study 9006239 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1265
Study 1626957 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative therapy-ACNU
Number of subjects: 120
Study 1626957 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy
Number of subjects: 120
Study 1626957 — intervention group
Group type: EXPERIMENTAL
Intervention: ACNU combination group
Number of subjects: 120
Study 6497641 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 1 mg/kg (Group 1)
Number of subjects: 3
Study 6497641 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 1 mg/kg (Group 2)
Number of subjects: 3
Study 6497641 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 4 mg/kg (Group 3)
Number of subjects: 3
Study 2940028 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 26242
Study 2940028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BCG vaccination)
Number of subjects: 26242
Study 29490702 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with stakeholders and public to identify recruitment uncertainties
Number of subjects: 790
Study 29490702 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritisation of recruitment questions through a workshop
Number of subjects: 790
Study 27340931 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) supplementation at 4 g/day
Number of subjects: 32
Study 27340931 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 24500851 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeCath Twin (LC)
Number of subjects: 80
Study 24500851 — intervention group
Group type: COMPARATOR
Intervention: Tesio catheter (TC)
Number of subjects: 80
Study 22091734 — intervention group
Group type: EXPERIMENTAL
Intervention: VLS GlideScope
Number of subjects: 50
Study 22091734 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐Mac Storz
Number of subjects: 50
Study 22091734 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath
Number of subjects: 50
Study 22091734 — intervention group
Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 50
Study 20392399 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (100 microg, 4 hourly, maximum of 2 doses)
Number of subjects: 100
Study 20392399 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (50 microg, 4 hourly, maximum of 2 doses)
Number of subjects: 100
Study 27950588 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive range of motion (ROM) exercises with postural sensory therapy
Number of subjects: 73
Study 27950588 — intervention group
Group type: COMPARATOR
Intervention: Postural sensory therapy alone (PS)
Number of subjects: 73
Study 27950588 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapy protocols
Number of subjects: 73
Study 16831792 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 240
Study 16831792 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 240
Study 16831792 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 240
Study 14570643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% continuous infusion at 5 mL/h for up to 48 h after surgery
Number of subjects: 24
Study 14570643 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 24
Study 14570643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% continuous infusion
Number of subjects: 24
Study 10761161 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (EES) 200 mg given orally 10 minutes after i.m. treatments
Number of subjects: 15
Study 10761161 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular saline (SAL, 0.5 ml), scopolamine (SCP, 0.1 mg), or promethazine (PMZ, 25 mg)
Number of subjects: 15
Study 8883527 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol at 320 mg I/ml (IOD‐320)
Number of subjects: 49
Study 8883527 — intervention group
Group type: COMPARATOR
Intervention: Iohexol at 300 mg I/ml (IOH‐300)
Number of subjects: 49
Study 1314242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (dF)
Number of subjects: 42
Study 1314242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3913724 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 17
Study 3913724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30932917 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise program plus vaginal electrotherapy
Number of subjects: 30
Study 30932917 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercise program
Number of subjects: 30
Study 30123582 — intervention group
Group type: EXPERIMENTAL
Intervention: CDR+ group (induced cognitive dietary restraint)
Number of subjects: 60
Study 30123582 — intervention group
Group type: COMPARATOR
Intervention: CDR- group (no induced cognitive dietary restraint)
Number of subjects: 60
Study 30123582 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CDR+ and CDR-)
Number of subjects: 60
Study 26549402 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg/d)
Number of subjects: 150
Study 26549402 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg/d)
Number of subjects: 150
Study 26549402 — intervention group
Group type: COMPARATOR
Intervention: Non-PPI users
Number of subjects: 150
Study 23900900 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training for 8 weeks
Number of subjects: 23
Study 23900900 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 22306375 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate Clostridium difficile toxoid vaccine (2 μg, 10 μg, or 50 μg)
Number of subjects: 98
Study 22306375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 19487925 — intervention group
Group type: EXPERIMENTAL
Intervention: Quifenadine (2 mg kg(‐1) day(‐1); n = 54)
Number of subjects: 104
Study 19487925 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (9 mg kg(‐1) day(‐1); n = 50)
Number of subjects: 104
Study 19487925 — intervention group
Group type: EXPERIMENTAL
Intervention: Quifenadine
Number of subjects: 104
Study 19487925 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 104
Study 18668016 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRI
Number of subjects: 0
Study 18668016 — intervention group
Group type: COMPARATOR
Intervention: SSRI
Number of subjects: 0
Study 15543591 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alpha‐2b induction (6 MU daily for 2 weeks) followed by 6 MU thrice weekly for 46 weeks (IFN/R group)
Number of subjects: 48
Study 15543591 — intervention group
Group type: COMPARATOR
Intervention: Pegylated IFN alpha‐2b (1.5 microg/kg) weekly for 48 weeks in combination with ribavirin (600‐1,000 mg daily) (PEG/R group)
Number of subjects: 48
Study 12784066 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB 2086 gel (3%)
Number of subjects: 0
Study 12784066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9890618 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-term neonates RBC
Number of subjects: 25
Study 9890618 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants RBC
Number of subjects: 25
Study 9890618 — intervention group
Group type: COMPARATOR
Intervention: Spherocytes
Number of subjects: 25
Study 9890618 — intervention group
Group type: COMPARATOR
Intervention: Elliptocytes
Number of subjects: 25
Study 9890618 — intervention group
Group type: COMPARATOR
Intervention: Stomatocytes
Number of subjects: 25
Study 9890618 — intervention group
Group type: COMPARATOR
Intervention: Immature RBC and knizocytes
Number of subjects: 25
Study 9890618 — intervention group
Group type: COMPARATOR
Intervention: Keratocytes, akantocytes, and elliptocytes
Number of subjects: 25
Study 9890618 — intervention group
Group type: COMPARATOR
Intervention: RBC volume
Number of subjects: 25
Study 8777104 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1 administered 2 min after maximum block (intense block group)
Number of subjects: 43
Study 8777104 — intervention group
Group type: COMPARATOR
Intervention: Edrophonium 1 mg kg‐1 administered after 10% recovery of T1 (conventional reversal group)
Number of subjects: 43
Study 8777104 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery (spontaneous recovery group)
Number of subjects: 43
Study 8777104 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1 (intense block group)
Number of subjects: 43
Study 8777104 — intervention group
Group type: COMPARATOR
Intervention: Edrophonium 1 mg kg‐1 (conventional reversal group)
Number of subjects: 43
Study 8777104 — intervention group
Group type: COMPARATOR
Intervention: Edrophonium 1 mg kg‐1 (spontaneous recovery group)
Number of subjects: 43
Study 1802194 — intervention group
Group type: COMPARATOR
Intervention: Placebo with cardiovasoprotective diet
Number of subjects: 133
Study 1802194 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (180 mg daily) with fat-modified control diet
Number of subjects: 133
Study 6185209 — intervention group
Group type: EXPERIMENTAL
Intervention: BLM‐MTX (bleomycin 30 mg intravenously twice weekly, methotrexate 25 mg intravenously twice weekly for 2 1/2 and two weeks, respectively)
Number of subjects: 39
Study 6185209 — intervention group
Group type: COMPARATOR
Intervention: CMF (methotrexate 25 mg twice weekly for two weeks, Cytoxan 100 mg/day for two weeks, 5‐FU 500 mg twice weekly for 1 1/2 weeks)
Number of subjects: 39
Study 28891903 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized Regenerated Cellulose (ORC)
Number of subjects: 24
Study 28891903 — intervention group
Group type: COMPARATOR
Intervention: Osteon II (Control)
Number of subjects: 24
Study 26514959 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endo-epicardial scar homogenization
Number of subjects: 0
Study 26514959 — intervention group
Group type: COMPARATOR
Intervention: Endocardial scar homogenization only (control group)
Number of subjects: 0
Study 23670111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful awareness/acceptance (MSER)
Number of subjects: 79
Study 23670111 — intervention group
Group type: COMPARATOR
Intervention: Attention-control treatment, healthy lifestyle tips (HT)
Number of subjects: 79
Study 21107917 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental subjects (ES) who walked average distances of 2.7±0.6 km day(‐1) during the experimental period.
Number of subjects: 20
Study 21107917 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (CS) who ran average distances of 9.8±1.7 km day(‐1) during the experimental period.
Number of subjects: 20
Study 19298338 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (duration 3 to 5 days)
Number of subjects: 576
Study 19298338 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (duration 5 to 10 days)
Number of subjects: 576
Study 17854244 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI) for 4 weeks
Number of subjects: 35
Study 17854244 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (NRI) for 4 weeks
Number of subjects: 35
Study 15187801 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 183
Study 15187801 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-type headache
Number of subjects: 183
Study 15187801 — intervention group
Group type: COMPARATOR
Intervention: Headache-free
Number of subjects: 183
Study 11686818 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B 3D Plaque Remover D15
Number of subjects: 82
Study 11686818 — intervention group
Group type: COMPARATOR
Intervention: Rowenta Dentasonic MH921S
Number of subjects: 82
Study 9215844 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (40,000 U/h)
Number of subjects: 42
Study 9215844 — intervention group
Group type: COMPARATOR
Intervention: Urokinase with heparin (320 U/h)
Number of subjects: 42
Study 7584270 — intervention group
Group type: EXPERIMENTAL
Intervention: lag6 (repeated after six intervening items)
Number of subjects: 0
Study 7584270 — intervention group
Group type: COMPARATOR
Intervention: lag0 (repeated immediately)
Number of subjects: 0
Study 3111812 — intervention group
Group type: EXPERIMENTAL
Intervention: Transderm-Nitro
Number of subjects: 38
Study 3111812 — intervention group
Group type: COMPARATOR
Intervention: Nitro-Dur
Number of subjects: 38
Study 3111812 — intervention group
Group type: COMPARATOR
Intervention: Nitrodisc
Number of subjects: 38
Study 3111812 — intervention group
Group type: EXPERIMENTAL
Intervention: All three products
Number of subjects: 38
Study 29758039 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.075 mg, intravenous)
Number of subjects: 120